Cédric Menard

5.9k total citations · 1 hit paper
45 papers, 2.8k citations indexed

About

Cédric Menard is a scholar working on Immunology, Genetics and Oncology. According to data from OpenAlex, Cédric Menard has authored 45 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Immunology, 19 papers in Genetics and 13 papers in Oncology. Recurrent topics in Cédric Menard's work include Immune Cell Function and Interaction (17 papers), Mesenchymal stem cell research (14 papers) and Immunotherapy and Immune Responses (10 papers). Cédric Menard is often cited by papers focused on Immune Cell Function and Interaction (17 papers), Mesenchymal stem cell research (14 papers) and Immunotherapy and Immune Responses (10 papers). Cédric Menard collaborates with scholars based in France, Italy and United States. Cédric Menard's co-authors include François Ghiringhelli, Laurence Zitvogel, François Martin, S. Roux, Axel Le Cesne, Sylvain Ladoire, Bruno Chauffert, Éric Solary, Karin Tarte and Nathalie Chaput and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Cédric Menard

44 papers receiving 2.8k citations

Hit Papers

Metronomic cyclophosphamide regimen selectively depletes ... 2006 2026 2012 2019 2006 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
    2006 968 citations François Ghiringhelli, Cédric Menard et al. Cancer Immunology Immunotherapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cédric Menard France 25 1.5k 1.3k 497 468 372 45 2.8k
Michael P. Gustafson United States 28 1.2k 0.8× 1.3k 1.0× 482 1.0× 732 1.6× 275 0.7× 67 2.8k
Christophe Borg France 22 1.3k 0.8× 652 0.5× 658 1.3× 500 1.1× 370 1.0× 48 2.3k
Fabrizio Vianello Italy 18 801 0.5× 901 0.7× 408 0.8× 520 1.1× 159 0.4× 89 2.2k
Steven C. Ziesmer United States 35 1.5k 1.0× 1.2k 0.9× 716 1.4× 580 1.2× 141 0.4× 65 3.2k
Deepak A. Rao United States 30 1.4k 0.9× 396 0.3× 166 0.3× 757 1.6× 513 1.4× 74 3.0k
Alexander Kiani Germany 25 623 0.4× 1.1k 0.8× 394 0.8× 680 1.5× 267 0.7× 78 2.7k
Kent W. Christopherson United States 22 1.0k 0.7× 1.4k 1.0× 354 0.7× 1.0k 2.2× 234 0.6× 46 2.9k
Giuseppina Bonanno Italy 25 859 0.6× 690 0.5× 579 1.2× 1.1k 2.3× 405 1.1× 52 2.6k
Sydney Gordon United States 8 1.7k 1.1× 1.4k 1.0× 105 0.2× 740 1.6× 185 0.5× 10 2.8k
Nadine Benhamouda France 17 1.2k 0.8× 1.3k 0.9× 187 0.4× 1.0k 2.2× 546 1.5× 36 3.0k

Countries citing papers authored by Cédric Menard

Since Specialization
Citations

This map shows the geographic impact of Cédric Menard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cédric Menard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cédric Menard more than expected).

Fields of papers citing papers by Cédric Menard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cédric Menard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cédric Menard. The network helps show where Cédric Menard may publish in the future.

Co-authorship network of co-authors of Cédric Menard

This figure shows the co-authorship network connecting the top 25 collaborators of Cédric Menard. A scholar is included among the top collaborators of Cédric Menard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cédric Menard. Cédric Menard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Menard, Cédric, Delphine Rossille, Joëlle Dulong, et al.. (2021). Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma. Blood Advances. 5(8). 2063–2074. 13 indexed citations
2.
Menard, Cédric, Joëlle Dulong, David Roulois, et al.. (2019). Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells. Stem Cells. 38(1). 146–159. 60 indexed citations
3.
Morschhauser, Franck, Gilles Salles, Steven Le Gouill, et al.. (2018). An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. Blood. 132(14). 1486–1494. 17 indexed citations
4.
5.
Borie, Raphaël, Cédric Menard, Jacques Cadranel, et al.. (2018). Rituximab for auto-immune alveolar proteinosis, a real life cohort study. Respiratory Research. 19(1). 74–74. 33 indexed citations
6.
Mahévas, Matthieu, Marc Michel, Benoît Vingert, et al.. (2015). Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. Journal of Autoimmunity. 62. 22–30. 50 indexed citations
7.
Tellier, Julie, Cédric Menard, Sandrine Roulland, et al.. (2014). Human t(14;18)positive germinal center B cells: a new step in follicular lymphoma pathogenesis?. Blood. 123(22). 3462–3465. 33 indexed citations
8.
Bassi, Giulio, Fabien Guilloton, Cédric Menard, et al.. (2014). Effects of a Ceramic Biomaterial on Immune Modulatory Properties and Differentiation Potential of Human Mesenchymal Stromal Cells of Different Origin. Tissue Engineering Part A. 21(3-4). 767–781. 15 indexed citations
9.
Menard, Cédric, Luciano Pacelli, Giulio Bassi, et al.. (2013). Clinical-Grade Mesenchymal Stromal Cells Produced Under Various Good Manufacturing Practice Processes Differ in Their Immunomodulatory Properties: Standardization of Immune Quality Controls. Stem Cells and Development. 22(12). 1789–1801. 154 indexed citations
10.
Bertheuil, Nicolas, et al.. (2013). Medial Thighplasty After Massive Weight Loss: Are There Any Risk Factors for Postoperative Complications?. Aesthetic Plastic Surgery. 38(1). 63–68. 27 indexed citations
11.
Trapani, Mariano Di, Giulio Bassi, Mario Ricciardi, et al.. (2013). Comparative Study of Immune Regulatory Properties of Stem Cells Derived from Different Tissues. Stem Cells and Development. 22(22). 2990–3002. 67 indexed citations
12.
Menard, Cédric & Karin Tarte. (2011). Immunosuppression et cellules souches mésenchymateuses. médecine/sciences. 27(3). 269–274. 6 indexed citations
13.
14.
Tursz, Thomas, et al.. (2010). Imatinib Mesylate (Gleevec©): Targeted Therapy Against Cancer with Immune Properties. Endocrine Metabolic & Immune Disorders - Drug Targets. 10(1). 1–7. 5 indexed citations
15.
Mignot, Grégoire, Evelyn Ullrich, Mathieu Bonmort, et al.. (2008). The Critical Role of IL-15 in the Antitumor Effects Mediated by the Combination Therapy Imatinib and IL-2. The Journal of Immunology. 180(10). 6477–6483. 39 indexed citations
16.
Menard, Cédric, François Martin, Lionel Apétoh, Florence Bouyer, & François Ghiringhelli. (2008). Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunology Immunotherapy. 57(11). 1579–1587. 129 indexed citations
17.
Ullrich, Evelyn, Cédric Menard, Caroline Flament, et al.. (2008). Dendritic cells and innate defense against tumor cells. Cytokine & Growth Factor Reviews. 19(1). 79–92. 35 indexed citations
18.
Taı̈eb, Julien, Nathalie Chaput, Noël E.C. Schartz, et al.. (2006). Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines. The Journal of Immunology. 176(5). 2722–2729. 159 indexed citations
19.
Ghiringhelli, François, Cédric Menard, Sylvain Ladoire, et al.. (2006). Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunology Immunotherapy. 56(5). 641–648. 968 indexed citations breakdown →
20.
Ghiringhelli, François, Cédric Menard, François Martin, & Laurence Zitvogel. (2006). The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunological Reviews. 214(1). 229–238. 216 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael P. Gustafson Breakdown of academic impact, for papers by Christophe Borg Breakdown of academic impact, for papers by Fabrizio Vianello Breakdown of academic impact, for papers by Steven C. Ziesmer Breakdown of academic impact, for papers by Deepak A. Rao Breakdown of academic impact, for papers by Alexander Kiani Breakdown of academic impact, for papers by Kent W. Christopherson Breakdown of academic impact, for papers by Giuseppina Bonanno Breakdown of academic impact, for papers by Sydney Gordon Breakdown of academic impact, for papers by Nadine Benhamouda
Rankless by CCL
2026